The Whitrod family launched Genetic Cures for Kids in the hopes of finding a treatment for their daughter with hereditary ...

The firm will use the money to advance its lead FAP-targeting radioligand candidate into clinical development.

The firm will use the funds to conduct a Phase I/II trial of an adoptive cell therapy designed to activate T regulatory cells against cancer.

The firm is hoping to show that the RNAi drug can treat HoFH by reducing production of ANGPTL3, which regulates lipid and lipoprotein metabolism.

Data from a Phase I trial of Avmapki Fakzynja also supports the regimen's tolerability and suggests its potential activity in ...

The organizations launched the center with a $20 million CZI grant to build on the success of the first personalized CRISPR base-editing therapy.

Cero will use Invivoscribe's multiparametric flow cytometry assay to detect minimal residual disease in patients and evaluate the therapy's efficacy.

The Phase II trial will compare progression-free survival in lung cancer patients treated according to their molecular subtypes.

The trial will test the drug in metastatic castration-resistant prostate cancer patients with low alkaline phosphatase levels, a marker of less advanced disease.

The law, slated to take effect in September, requires health plans to cover the treatment given by in-network providers, not ...

The firm is launching a Phase II trial of its dendritic cell vaccine following promising preliminary efficacy and favorable safety results in Phase I.

Using 400 real-world patient cases, the CARE platform correctly classified 99.5 percent of cases according to NCCN guidelines ...